Exact Mass: 487.19563220000003

Exact Mass Matches: 487.19563220000003

Found 500 metabolites which its exact mass value is equals to given mass value 487.19563220000003, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

YC 170

3-Pyridinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-2,6-dimethyl-5-((phenylamino)carbonyl)-, 2-(2-pyridinyl)ethyl ester

C28H26ClN3O3 (487.1662596000001)

Myxothiazol

Myxothiazol A

C25H33N3O3S2 (487.1963228)

A 2,4-bi-1,3-thiazole substituted at the 4-position with a (1E,3S,4R,5E)-7-amino-3,5-dimethoxy-4-methyl-7-oxohepta-1,5-dien-1-yl] group and at the 2-position with a (2S,3E,5E)-7-methylocta-3,5-dien-2-yl group. It is an inhibitor of coenzyme Q - cytochrome c reductase. D000890 - Anti-Infective Agents > D000935 - Antifungal Agents D004791 - Enzyme Inhibitors

Dasatinib

N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide

C22H26ClN7O2S (487.1557126000001)

Dasatinib is only found in individuals that have used or taken this drug. It is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFR&beta. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression. L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EA - Bcr-abl tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

Ac-Ser-Asp-Lys-Pro-OH

(2S)-1-[(2S)-6-amino-2-{[(2S)-3-carboxy-2-{[(2S)-1,3-dihydroxy-2-[(1-hydroxyethylidene)amino]propylidene]amino}-1-hydroxypropylidene]amino}hexanoyl]pyrrolidine-2-carboxylic acid

C20H33N5O9 (487.2278168)

Ac-Ser-Asp-Lys-Pro-OH, also known as Ac-ser-asp-lys-pro or AcSDKP-NH2, is classified as a member of the Oligopeptides. Oligopeptides are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds. Ac-Ser-Asp-Lys-Pro-OH is considered to be practically insoluble (in water) and acidic D020011 - Protective Agents > D011837 - Radiation-Protective Agents D006133 - Growth Substances > D006131 - Growth Inhibitors C26170 - Protective Agent

Acetyl-Ser-Asp-Lys-Pro

1-{6-amino-2-[3-carboxy-2-(2-acetamido-3-hydroxypropanamido)propanamido]hexanoyl}pyrrolidine-2-carboxylic acid

C20H33N5O9 (487.2278168)

D020011 - Protective Agents > D011837 - Radiation-Protective Agents D006133 - Growth Substances > D006131 - Growth Inhibitors

2,2,2-Trifluoro-N-((1R,2S)-1-((1-(4-fluorophenyl)-1H-indazol-5-yl)oxy)-1-(3-methoxyphenyl)-2-propanyl)acetamide

C25H21F4N3O3 (487.15189640000006)

(2S)-3-[[2-[(5R)-3-(4-Carbamimidoylphenyl)-4,5-dihydro-1,2-oxazol-5-yl]acetyl]amino]-2-[(3-methylphenyl)sulfonylamino]propanoic acid

(2S)-3-[[2-[(5R)-3-(4-Carbamimidoylphenyl)-4,5-dihydro-1,2-oxazol-5-yl]acetyl]amino]-2-[(3-methylphenyl)sulphonylamino]propanoic acid

C22H25N5O6S (487.152547)

Methylsulfonyl 4-[(2-carbamimidoyl-3,4-dihydro-1H-isoquinolin-7-yl)oxymethyl]-1-pyridin-4-ylpiperidine-4-carboxylate

Methanesulphonyl 4-{[(2-carbamimidoyl-1,2,3,4-tetrahydroisoquinolin-7-yl)oxy]methyl}-1-(pyridin-4-yl)piperidine-4-carboxylic acid

C23H29N5O5S (487.18893040000006)

Malvidin 3-alpha-L-galactoside

2-(3-ethenyl-5-methoxy-4-methylphenyl)-5,7-dihydroxy-3-{[(2R,3S,4R,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1λ⁴-chromen-1-ylium

C25H27O10 (487.1604142)

Malvidin 3-alpha-l-galactoside is practically insoluble (in water) and a very weakly acidic compound (based on its pKa). Malvidin 3-alpha-l-galactoside can be found in highbush blueberry, which makes malvidin 3-alpha-l-galactoside a potential biomarker for the consumption of this food product.

Pemigatinib

11-(2,6-difluoro-3,5-dimethoxyphenyl)-13-ethyl-4-[(morpholin-4-yl)methyl]-5,7,11,13-tetraazatricyclo[7.4.0.0^{2,6}]trideca-1,3,6,8-tetraen-12-one

C24H27F2N5O4 (487.2031006000001)

L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EN - Fibroblast growth factor receptor (fgfr) tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor

Sarecycline

(4S,4AS,5ar,12as)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-7-{[methoxy(methyl)amino]methyl}-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboximidate

C24H29N3O8 (487.1954554)

J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01A - Tetracyclines > J01AA - Tetracyclines C784 - Protein Synthesis Inhibitor > C1595 - Tetracycline Antibiotic D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents C254 - Anti-Infective Agent > C258 - Antibiotic D003879 - Dermatologic Agents

Fiscalin C

C27H29N5O4 (487.22194340000004)

CONFIDENCE Penicillium corvianum

A spiruchostatin with molecular formula C21H33N3O6S2 originally isolated from a Pseudomonas culture broth. D004791 - Enzyme Inhibitors > D056572 - Histone Deacetylase Inhibitors

Folinic acid

C21H25N7O7 (487.181538)

pokepola ester

C23H38NO8P (487.2334918)

4-hydroxy-3-methoxyphenylacetonitrile 4-O-beta-D-glucopyranosyl(1->6)-beta-D-glucopyranoside|adenophoraside B

C21H29NO12 (487.16896740000004)

C18H33NO14

C18H33NO14 (487.1900958)

Cys Ala Pro Pro Thr

C20H33N5O7S (487.21005880000007)

Trp Pro Trp

C27H29N5O4 (487.22194340000004)

Val Ser Gly Pro Glu

C20H33N5O9 (487.2278168)

Pro Trp Trp

C27H29N5O4 (487.22194340000004)

Dasatinib (BMS-354825)

C22H26ClN7O2S (487.1557126000001)

4-[[4-hydroxy-2-(2-methylpropyl)-1-oxo-3,3a-dihydro-2H-imidazo[1,2-a]indol-4-yl]methyl]-1-methyl-2,4-dihydro-1H-pyrazino[2,1-b]quinazoline-3,6-dione

C27H29N5O4 (487.22194340000004)

Ala Asp Pro Trp

(3S)-3-[(2S)-2-aminopropanamido]-4-[(2S)-2-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]carbamoyl}pyrrolidin-1-yl]-4-oxobutanoic acid

C23H29N5O7 (487.2066884)

Ala Asp Trp Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-carboxypropanamido]-3-(1H-indol-3-yl)propanoyl]pyrrolidine-2-carboxylic acid

C23H29N5O7 (487.2066884)

Ala Phe His Asn

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-phenylpropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanoic acid

C22H29N7O6 (487.2179214)

Ala Phe Asn His

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-phenylpropanamido]-3-carbamoylpropanamido]-3-(1H-imidazol-4-yl)propanoic acid

C22H29N7O6 (487.2179214)

Ala His Phe Asn

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-phenylpropanamido]-3-carbamoylpropanoic acid

C22H29N7O6 (487.2179214)

Ala His Asn Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanamido]-3-phenylpropanoic acid

C22H29N7O6 (487.2179214)

Ala Asn Phe His

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-carbamoylpropanamido]-3-phenylpropanamido]-3-(1H-imidazol-4-yl)propanoic acid

C22H29N7O6 (487.2179214)

Ala Asn His Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-carbamoylpropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-phenylpropanoic acid

C22H29N7O6 (487.2179214)

Ala Pro Asp Trp

(3S)-3-{[(2S)-1-[(2S)-2-aminopropanoyl]pyrrolidin-2-yl]formamido}-3-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]carbamoyl}propanoic acid

C23H29N5O7 (487.2066884)

Ala Pro Trp Asp

(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-aminopropanoyl]pyrrolidin-2-yl]formamido}-3-(1H-indol-3-yl)propanamido]butanedioic acid

C23H29N5O7 (487.2066884)

Ala Trp Asp Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(1H-indol-3-yl)propanamido]-3-carboxypropanoyl]pyrrolidine-2-carboxylic acid

C23H29N5O7 (487.2066884)

Ala Trp Pro Asp

(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-aminopropanamido]-3-(1H-indol-3-yl)propanoyl]pyrrolidin-2-yl]formamido}butanedioic acid

C23H29N5O7 (487.2066884)

Cys His Lys Thr

(2S,3R)-2-[(2S)-6-amino-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-(1H-imidazol-4-yl)propanamido]hexanamido]-3-hydroxybutanoic acid

C19H33N7O6S (487.2212918000001)

Cys His Gln Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-(1H-imidazol-4-yl)propanamido]-4-carbamoylbutanamido]-3-hydroxybutanoic acid

C18H29N7O7S (487.18490840000004)

Cys His Thr Lys

(2S)-6-amino-2-[(2S,3R)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-hydroxybutanamido]hexanoic acid

C19H33N7O6S (487.2212918000001)

Cys His Thr Gln

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-hydroxybutanamido]-4-carbamoylbutanoic acid

C18H29N7O7S (487.18490840000004)

Cys Lys His Thr

(2S,3R)-2-[(2S)-2-[(2S)-6-amino-2-[(2R)-2-amino-3-sulfanylpropanamido]hexanamido]-3-(1H-imidazol-4-yl)propanamido]-3-hydroxybutanoic acid

C19H33N7O6S (487.2212918000001)

Cys Lys Thr His

(2S)-2-[(2S,3R)-2-[(2S)-6-amino-2-[(2R)-2-amino-3-sulfanylpropanamido]hexanamido]-3-hydroxybutanamido]-3-(1H-imidazol-4-yl)propanoic acid

C19H33N7O6S (487.2212918000001)

Cys Gln His Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-4-carbamoylbutanamido]-3-(1H-imidazol-4-yl)propanamido]-3-hydroxybutanoic acid

C18H29N7O7S (487.18490840000004)

Cys Gln Thr His

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-4-carbamoylbutanamido]-3-hydroxybutanamido]-3-(1H-imidazol-4-yl)propanoic acid

C18H29N7O7S (487.18490840000004)

Cys Thr His Lys

(2S)-6-amino-2-[(2S)-2-[(2S,3R)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-hydroxybutanamido]-3-(1H-imidazol-4-yl)propanamido]hexanoic acid

C19H33N7O6S (487.2212918000001)

Cys Thr His Gln

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-hydroxybutanamido]-3-(1H-imidazol-4-yl)propanamido]-4-carbamoylbutanoic acid

C18H29N7O7S (487.18490840000004)

Cys Thr Lys His

(2S)-2-[(2S)-6-amino-2-[(2S,3R)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-hydroxybutanamido]hexanamido]-3-(1H-imidazol-4-yl)propanoic acid

C19H33N7O6S (487.2212918000001)

Cys Thr Gln His

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-hydroxybutanamido]-4-carbamoylbutanamido]-3-(1H-imidazol-4-yl)propanoic acid

C18H29N7O7S (487.18490840000004)

Asp Ala Pro Trp

(3S)-3-amino-3-{[(2S)-1-[(2S)-2-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]carbamoyl}pyrrolidin-1-yl]-1-oxopropan-2-yl]carbamoyl}propanoic acid

C23H29N5O7 (487.2066884)

Asp Ala Trp Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carboxypropanamido]propanamido]-3-(1H-indol-3-yl)propanoyl]pyrrolidine-2-carboxylic acid

C23H29N5O7 (487.2066884)

Asp Glu Lys Pro

(2S)-1-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-carboxypropanamido]-4-carboxybutanamido]hexanoyl]pyrrolidine-2-carboxylic acid

C20H33N5O9 (487.2278168)

Asp Glu Pro Lys

(2S)-6-amino-2-{[(2S)-1-[(2S)-2-[(2S)-2-amino-3-carboxypropanamido]-4-carboxybutanoyl]pyrrolidin-2-yl]formamido}hexanoic acid

C20H33N5O9 (487.2278168)

Asp Glu Pro Gln

(4S)-4-[(2S)-2-amino-3-carboxypropanamido]-5-[(2S)-2-{[(1S)-3-carbamoyl-1-carboxypropyl]carbamoyl}pyrrolidin-1-yl]-5-oxopentanoic acid

C19H29N5O10 (487.19143340000005)

Asp Glu Gln Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carboxypropanamido]-4-carboxybutanamido]-4-carbamoylbutanoyl]pyrrolidine-2-carboxylic acid

C19H29N5O10 (487.19143340000005)

Asp Lys Glu Pro

(2S)-1-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-carboxypropanamido]hexanamido]-4-carboxybutanoyl]pyrrolidine-2-carboxylic acid

C20H33N5O9 (487.2278168)

Asp Lys Pro Glu

(2S)-2-{[(2S)-1-[(2S)-6-amino-2-[(2S)-2-amino-3-carboxypropanamido]hexanoyl]pyrrolidin-2-yl]formamido}pentanedioic acid

C20H33N5O9 (487.2278168)

Asp Pro Ala Trp

(3S)-3-amino-4-[(2S)-2-{[(1S)-1-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]carbamoyl}ethyl]carbamoyl}pyrrolidin-1-yl]-4-oxobutanoic acid

C23H29N5O7 (487.2066884)

Asp Pro Glu Lys

(2S)-6-amino-2-[(2S)-2-{[(2S)-1-[(2S)-2-amino-3-carboxypropanoyl]pyrrolidin-2-yl]formamido}-4-carboxybutanamido]hexanoic acid

C20H33N5O9 (487.2278168)

Asp Pro Glu Gln

(4S)-4-{[(2S)-1-[(2S)-2-amino-3-carboxypropanoyl]pyrrolidin-2-yl]formamido}-4-{[(1S)-3-carbamoyl-1-carboxypropyl]carbamoyl}butanoic acid

C19H29N5O10 (487.19143340000005)

Asp Pro Lys Glu

(2S)-2-[(2S)-6-amino-2-{[(2S)-1-[(2S)-2-amino-3-carboxypropanoyl]pyrrolidin-2-yl]formamido}hexanamido]pentanedioic acid

C20H33N5O9 (487.2278168)

Asp Pro Gln Glu

(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-amino-3-carboxypropanoyl]pyrrolidin-2-yl]formamido}-4-carbamoylbutanamido]pentanedioic acid

C19H29N5O10 (487.19143340000005)

Asp Pro Arg Thr

(2S,3R)-2-[(2S)-2-{[(2S)-1-[(2S)-2-amino-3-carboxypropanoyl]pyrrolidin-2-yl]formamido}-5-carbamimidamidopentanamido]-3-hydroxybutanoic acid